Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra for the Patients with NASH That Have Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals in the NEWS Yesterday, March 14, 2024 Madrigal Pharmaceuticals ( MDGL ) announced that the U.S. FDA has granted accelerated approval for the firm’s product Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults...

March 15, 2024

AbbVie Inc's Two Different, Yet, Positive Impacting News

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biopharma, a clinical stage biopharmaceutical firm focused on...

March 26, 2024

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead Sciences ( GILD ) announced that the U.S. FDA lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination...

April 13, 2022

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial innovating firms that are challenging the Top-Tier firms that are currently generating billions of dollars in selling revenues. These firms are developers of products...

March 28, 2024

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings News Arcturus Therapeutics Holdings ( ARCT ) shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19. The ongoing Phase 1/2/3 registrational study, sponsored by Arcturus’ collaborator Vinbiocare Biotechnology...

April 20, 2022

FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

argenx in the NEWS argenx SE ( ARGX ) announced that the U.S. FDA has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy ( CIDP ). VYVGART Hytrulo is approved for CIDP as...

June 24, 2024

Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

Nurix Therapeutics in the NEWS On June 16, 2024, Nurix Therapeutics ( NRIX ) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase ( BTK ), being evaluated in an ongoing Phase...

June 25, 2024

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Verona Pharma in the NEWS Yesterday, June 26, 2024, Verona Pharma plc ( VRNA ) announced that the US FDA has approved Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease ( COPD ) in adult patients. Ohtuvayre is...

June 27, 2024

Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals in the NEWS Yesterday, Syndax Pharmaceuticals (NASDAQ: SNDX ) announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory ( R/R ) KMT2A-rearranged ( KMT2Ar ) acute myeloid leukemia ( AML )...

April 9, 2024

Answers About Vertex Pharmaceuticals Acquisition of Alpine Immune. See Also: Important News from Coya Therapeutics on ALS

Vertex Pharmaceuticals Acquisition of Alpine Immune Sciences We start this posting by answering a question by savvy investors regarding Vertex Pharmaceuticals' ( VRTX ) decision to acquire Alpine Immune Sciences ( ALPN ) . The reason for the question is...

April 11, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024